Samsara BioCapital LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)

Samsara BioCapital LLC purchased a new stake in shares of Palvella Therapeutics (NASDAQ:PVLA) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 679,486 shares of the company’s stock, valued at approximately $8,154,000. Palvella Therapeutics comprises approximately 1.1% of Samsara BioCapital LLC’s portfolio, making the stock its 17th biggest holding. Samsara BioCapital LLC owned approximately 6.06% of Palvella Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of PVLA. Geode Capital Management LLC purchased a new stake in Palvella Therapeutics in the 4th quarter valued at about $171,000. Renaissance Technologies LLC acquired a new stake in shares of Palvella Therapeutics in the fourth quarter valued at $256,000. BML Capital Management LLC purchased a new position in Palvella Therapeutics during the 4th quarter valued at about $506,000. ADAR1 Capital Management LLC acquired a new position in Palvella Therapeutics in the 4th quarter valued at about $1,736,000. Finally, Nantahala Capital Management LLC acquired a new position in Palvella Therapeutics in the 4th quarter valued at about $3,001,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

PVLA stock opened at $23.44 on Wednesday. The stock has a market cap of $258.29 million, a P/E ratio of -1.94 and a beta of 0.10. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $29.27. The firm has a fifty day simple moving average of $24.27.

Insider Activity at Palvella Therapeutics

In related news, Director George M. Jenkins acquired 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 9th. The shares were purchased at an average price of $20.13 per share, with a total value of $50,325.00. Following the completion of the acquisition, the director now owns 183,171 shares in the company, valued at approximately $3,687,232.23. This represents a 1.38 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 6.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PVLA. TD Cowen initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price on the stock. Stifel Nicolaus assumed coverage on Palvella Therapeutics in a report on Wednesday, March 26th. They issued a “buy” rating and a $45.00 target price for the company. Jones Trading began coverage on Palvella Therapeutics in a report on Tuesday, March 25th. They set a “buy” rating and a $45.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, April 1st. Finally, Chardan Capital started coverage on shares of Palvella Therapeutics in a research note on Wednesday, April 9th. They set a “buy” rating and a $50.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Palvella Therapeutics has an average rating of “Buy” and a consensus price target of $44.43.

Palvella Therapeutics Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.